Takeda Receives FDA Approval to Expand the Use of Hyqvia to Treat Primary Immunodeficiency in Children

CAMBRIDGE, Mass.--(BUSINESS WIRE) April 11, 2023 --Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental biologics license application (sBLA) to expand the use of Hyqvia to treat...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news